支链氨基酸分解代谢受损是瘢痕疙瘩的代谢标志与治疗靶点
该研究整合五个转录组数据集分析瘢痕疙瘩中支链氨基酸(BCAA)分解代谢基因表达,并在临床样本中定量循环与组织BCAA水平,体外评估BCAA及代谢增强剂BT2对瘢痕疙瘩成纤维细胞(KFs)的影响。结果显示瘢痕疙瘩中72.5%的BCAA分解代谢基因系统性下调,循环与组织BCAA水平显著升高,亮氨酸是驱动KFs增殖与细胞外基质沉积的主要效应分子,药物增强BCAA分解代谢可有效逆转该表型。
要点
- 瘢痕疙瘩中72.5%的BCAA分解代谢基因系统性下调,构成代谢标志。
- 瘢痕疙瘩患者循环与组织BCAA水平显著升高。
- 亮氨酸驱动KFs增殖与ECM沉积,增强BCAA分解代谢可逆转。
核心结论
- BCAA分解代谢受损尤其是亮氨酸蓄积在瘢痕疙瘩形成中起重要作用,是潜在治疗靶点。
研究设计与样本
- 整合分析五个转录组数据集,并进行功能富集、蛋白互作网络、微环境分析和基因集变异分析。
- 在临床样本中定量循环与组织BCAA水平。
- 体外评估特定BCAA及代谢增强剂BT2对瘢痕疙瘩成纤维细胞增殖和ECM产生的影响。
主要发现
- 瘢痕疙瘩中72.5%的BCAA分解代谢基因系统性下调,形成BCAA蓄积的代谢微环境。
- 分子分型识别出BCAA分解代谢缺陷亚型,与上皮-间质转化和血管生成活性增强相关。
- 临床验证显示瘢痕疙瘩患者循环与组织BCAA水平显著升高。
- 体外实验确定亮氨酸是驱动KFs增殖和ECM沉积的主要代谢效应分子。
- 药理学增强BCAA分解代谢可有效挽救亮氨酸驱动的KFs表型。
临床怎么用
- BCAA分解代谢通路尤其是亮氨酸可作为瘢痕疙瘩的代谢标志与治疗靶点。
- 药理学增强BCAA分解代谢可能成为瘢痕疙瘩的潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Keloids are refractory proliferative scars driven by aberrant collagen deposition and metabolic remodeling. While branched-chain amino acids (BCAAs) are known to influence skin collagen synthesis, their specific roles and underlying regulatory mechanisms in keloid pathogenesis remain largely unexplored. METHODS: An integrated analysis of five transcriptomic datasets was conducted to characterize BCAA catabolic gene expression in keloids. We performed functional enrichment analysis, protein-protein interaction network construction, microenvironment profiling, and gene set variation analysis. Circulating and tissue BCAA levels were quantified in clinical samples. The functional impact of specific BCAAs and the metabolic enhancer BT2 on keloid fibroblasts (KFs) proliferation and extracellular matrix (ECM) production was assessed in vitro. RESULTS: The study reveals a systemic downregulation of 72.5% of BCAA catabolic genes in keloids, establishing impaired BCAA catabolism as a distinct metabolic hallmark. This comprehensive metabolic blockade creates a permissive metabolic microenvironment characterized by the accumulation of BCAAs. Molecular classification identifies a distinct BCAA catabolic-defective subtype; this cluster, defined by the coordinated dysregulation of multiple catabolic enzymes, correlates with enhanced epithelial-mesenchymal transition and angiogenic activity. Clinical validation confirms significantly higher circulating and tissue levels of BCAAs in keloid patients. In vitro experiments identify leucine as the primary metabolic effector that drives KFs proliferation and ECM deposition, a phenotype that can be effectively rescued by pharmacological enhancement of BCAA catabolism. CONCLUSION: This study highlights the importance of impaired BCAA catabolism, particularly leucine accumulation in keloid formation, providing new insights into keloid pathogenesis and potential therapeutic targets.
引用
- Zhang B, Li Y, Tan X, et al. Impaired branched-chain amino acid catabolism serves as a metabolic hallmark and therapeutic target in keloids. Burns. 2026. PMID: 42150395. doi:10.1016/j.burns.2026.108062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。